Cubist Systematic Strategies LLC Takes Position in Theravance Biopharma, Inc. $TBPH

Key Points

• Cubist Systematic Strategies LLC has acquired 46,972 shares of Theravance Biopharma, Inc., valued at around $419,000, making it a new investor in the company as reported in their recent SEC filing.
• Multiple hedge funds, including Northern Trust Corp and Bank of America Corp DE, have increased their stakes in Theravance Biopharma, indicating a strong interest from institutional investors, who now hold 99.1% of the company's stock.
• Equities analysts have raised Theravance Biopharma's rating to "strong-buy", with a consensus target price of $21.33, reflecting positive market sentiment towards the company's future performance.

Cubist Systematic Strategies LLC bought a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,972 shares of the biopharmaceutical company's stock, valued at approximately $419,000. Cubist Systematic Strategies LLC owned approximately 0.09% of Theravance Biopharma at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares in the last quarter. R Squared Ltd lifted its position in shares of Theravance Biopharma by 636.6% during the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Theravance Biopharma during the fourth quarter worth $119,000. Tabor Asset Management LP acquired a new position in shares of Theravance Biopharma during the first quarter worth $135,000. Finally, State of Wyoming increased its stake in shares of Theravance Biopharma by 36.2% in the first quarter. State of Wyoming now owns 17,909 shares of the biopharmaceutical company's stock worth $160,000 after buying an additional 4,758 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TBPH has been the subject of a number of research analyst reports. Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. B. Riley initiated coverage on shares of Theravance Biopharma in a research note on Friday. They issued a "buy" rating and a $28.00 price target for the company. BTIG Research lifted their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Finally, Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a research note on Tuesday, June 17th. Three analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Strong Buy" and a consensus price target of $23.00.

Theravance Biopharma Stock Down 3.7%

TBPH stock traded down $0.53 during trading on Tuesday, hitting $13.87. 450,603 shares of the company's stock traded hands, compared to its average volume of 506,332. Theravance Biopharma, Inc. has a 52 week low of $7.88 and a 52 week high of $14.55. The stock has a fifty day moving average price of $12.51 and a two-hundred day moving average price of $10.67. The stock has a market capitalization of $698.49 million, a price-to-earnings ratio of 57.79 and a beta of 0.05.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.